masitinib mesylate


( Last Updated : December 12, 2022)
Generic Name:
masitinib mesylate
Project Status:
Suspended
Therapeutic Area:
Amyotrophic lateral sclerosis (ALS)
Manufacturer:
AB Science SA
Brand Name:
Alsitek
Project Line:
Reimbursement Review
Project Number:
SR0766-000
NOC Status at Filing:
Pre NOC

Details

Manufacturer Requested Reimbursement Criteria1:
Masitinib mesylate film-coated tablets in combination with riluzole is indicated for treatment of adult patients with amyotrophic lateral sclerosis (ALS).
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Alsitek (masitinib mesylate) in combination with riluzole is indicated for treatment of adult patients with amyotrophic lateral sclerosis (ALS)
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openSeptember 29, 2022
Call for patient/clinician input closedNovember 18, 2022
Clarification:

- Patient input submission received from ALS Action Canada and ALS Society of Canada

Submission receivedOctober 28, 2022
Submission acceptedNovember 15, 2022
Clarification:

- Submission was not accepted for review on 11 Nov 2022

Review initiatedNovember 16, 2022
Clarification:

- Submission temporarily suspended

Draft CADTH review report(s) provided to sponsor for comment
Deadline for sponsors comments
CADTH review report(s) and responses to comments provided to sponsor
Expert committee meeting (initial)
Draft recommendation issued to sponsor
Draft recommendation posted for stakeholder feedback
End of feedback period